within Pharmacolibrary.Drugs.N_NervousSystem.N07C_AntivertigoPreparations.N07CA02_Cinnarizine;

model Cinnarizine
  extends Pharmacolibrary.Drugs.ATC.N.N07CA02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N07CA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cinnarizine is a piperazine derivative antihistamine commonly used to treat and prevent motion sickness, vertigo, and balance disorders. It acts as a selective calcium channel blocker and histamine H1 receptor antagonist. Although widely used in many countries, cinnarizine is not approved for use in the United States or some other regions.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult volunteers after a single oral dose administration.</p><h4>References</h4><ol><li><p>Oransa, HA, et al., &amp; El-Sabbagh, HM (2022). Novel Mucoadhesive Chitosomes as a Platform for Enhanced Oral Bioavailability of Cinnarizine. <i>International journal of nanomedicine</i> 17 5641–5660. DOI:<a href=\"https://doi.org/10.2147/IJN.S384494\">10.2147/IJN.S384494</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36452306/\">https://pubmed.ncbi.nlm.nih.gov/36452306</a></p></li><li><p>Li, BQ, et al., &amp; Wang, Y (2010). Effect of route of administration on the pharmacokinetics and toxicokinetics of cinnarizine in dogs. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 40(3) 197–201. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2010.03.013\">10.1016/j.ejps.2010.03.013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20307656/\">https://pubmed.ncbi.nlm.nih.gov/20307656</a></p></li><li><p>Berlin, M, et al., &amp; Dressman, JB (2014). Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 88(3) 795–806. DOI:<a href=\"https://doi.org/10.1016/j.ejpb.2014.08.011\">10.1016/j.ejpb.2014.08.011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25195981/\">https://pubmed.ncbi.nlm.nih.gov/25195981</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Cinnarizine;
